Early Signs of Perimenopause — What to Notice in Your 30s and Early 40s

If you're noticing changes in your 30s or early 40s and wondering whether it's too early to be perimenopause, the evidence says no. The earliest signs of perimenopause can appear years before the late-40s onset most consumer articles describe. The Stages of Reproductive Aging Workshop framework (STRAW+10) identifies a late reproductive stage in which subtle hormonal shifts begin while your cycles still look regular. The Study of Women's Health Across the Nation (SWAN) has documented average onset of the menopausal transition between 40 and 44. A meaningful minority of women enter it earlier. This article describes those early signals, what tests measure, and how to tell perimenopause apart from conditions that mimic it.

In this article

• When perimenopause actually begins relative to the late-40s assumption
• The eight earliest signs that are often dismissed as stress
• Why a single "normal" FSH result does not rule perimenopause out
• Better markers for early evaluation, and what each test reports
• Conditions that mimic early perimenopause
• A cycle-tracking template to use before a clinical workup
• When the pattern points to a deeper evaluation

When perimenopause actually begins (it's earlier than most articles say)

Some factors move that timing forward. Patient-education sources including Cleveland Clinic and the NHS report that smoking brings menopause forward by one to three years.

Perimenopause is the multi-year transition that ends one year after your final menstrual period. Median age of menopause in U.S. women is approximately 51, but the transition typically begins four to eight years earlier, and earlier still in some women. The STRAW+10 system divides the reproductive lifespan into seven stages. One is a late reproductive stage (Stage −3) in which cycles remain regular but subtle endocrine changes are already underway (Harlow et al., 2012).

In Stage −3, anti-Müllerian hormone (AMH) and inhibin B begin to decline. Follicle-stimulating hormone (FSH) becomes more variable across cycles, and luteal-phase progesterone output may shift downward. SWAN cohort data define the early menopausal transition (Stage −2) by persistent cycle-length variability of seven days or more between consecutive cycles (SWAN cohort publications). Your cycles can still arrive predictably while measurable hormonal change is already in progress.

The Menopause Society notes that a meaningful minority of women experience symptomatic perimenopause beginning in the mid-to-late 30s. It also notes that dismissing symptoms by age can delay appropriate evaluation (The Menopause Society). Reproductive aging is a continuum, and the earliest measurable shifts predate visible cycle changes by years.

A February 2025 study in npj Women's Health, run with Flo and the University of Virginia, surveyed 4,432 US women. Among those aged 30 to 35, 55.4% already scored in the moderate or severe range on the Menopause Rating Scale. Only 4.3% of that age group had consulted a clinician about it. Everyone in the sample used a cycle-tracking app, so it does not represent every woman.

The 8 earliest signs most women dismiss

The earliest signals are subtle and easy to attribute to work stress, parenting demands, or general aging. Eight patterns recur in the literature.

What you expect and what you get are often different. A global study published by Flo and The Menopause Society in January 2026 surveyed more than 17,000 women across 158 countries. Hot flashes were the most expected symptom at 71%, followed by sleep problems at 68% and weight change at 65%.

What women aged 35 and over actually reported looked different. Fatigue and exhaustion led at 83%, then irritability at 80% and depressive mood at 77%. Sleep problems and digestive issues were both reported by 76%. Digestive symptoms are not among the eight signs below, so log them too if they are new.

A shift in the character of your PMS

A change in the character of your premenstrual symptoms is one of the earliest signs of perimenopause. Symptoms that used to be mild become more intense, last longer, or change in quality: newly disrupted sleep, breast tenderness that lasts a week instead of two days, mood symptoms that arrive earlier in the luteal phase. SWAN data describe luteal-phase progesterone variability as one of the earliest measurable changes (Santoro et al., 2008). Suspect perimenopause when the shift holds across several cycles rather than one difficult month.

Sleep architecture change and waking between 2 and 4 a.m.

Sleep changes early in perimenopause, often before any hot flash. Falling asleep is preserved, but waking between 2 and 4 a.m. becomes routine. Polysomnographic studies in perimenopausal women document reduced slow-wave sleep and more nocturnal arousals, even before vasomotor symptoms appear (Baker et al., 2018).

A February 2025 meta-analysis in Frontiers in Neurology pooled 22 studies and 89,897 women across 10 countries. It put the prevalence of sleep disturbance during the menopausal transition at 50 to 55%. Depression and hot flashes were the two factors most strongly associated with it, at odds ratios of 2.73 and 2.70. Suspect perimenopause when the early-hours waking recurs most weeks and your sleep habits have not changed.

Reduced exercise tolerance and slower recovery

Workouts that used to feel routine start to require longer recovery in early perimenopause. Heart-rate recovery slows, and previously easy efforts feel harder. This often pre-dates any change in body composition, which is why it is easy to read as ordinary aging. Suspect perimenopause when your training load has not increased and the extra recovery time persists across several cycles.

The first cycle-length variability

The first cycle-length variability is the change that formally marks entry into the early menopausal transition. Cycles that were consistently 28 to 30 days begin to vary: a 26-day cycle followed by a 31-day cycle. Per STRAW+10, persistent variability of seven or more days defines entry into the early transition (Harlow et al., 2012). Suspect perimenopause when that seven-day swing repeats across consecutive cycles rather than appearing once.

New-onset anxiety that feels different from prior stress

New-onset anxiety in perimenopause is qualitatively different from prior stress. Women often describe it as a "buzzing" baseline rather than situational worry. It has been associated with the hormonal turbulence of the early transition (Bromberger et al., 2018). Suspect perimenopause when the anxiety has no clear trigger and tends to track with the luteal phase of your cycle.

A first hot flash around ovulation or the late luteal phase

A single "first-time" hot flash around ovulation or in the late luteal phase can be an early vasomotor signal of perimenopause. One episode of feeling unexpectedly hot or flushed is easy to dismiss, but it can be tied to estradiol fluctuation (NAMS position statements). Suspect perimenopause when the flush lands at the same point in your cycle more than once.

Libido shifts and new vaginal dryness

Libido shifts can predate cycle changes in perimenopause. A reduction in spontaneous desire, changes in arousal, or new vaginal dryness can all appear while your periods still look regular. The Endocrine Society notes that androgen and estradiol fluctuations both contribute (Endocrine Society clinical practice guidelines). Suspect perimenopause when the change persists over several months and no new medication or relationship factor explains it.

Subtle cognitive changes and word-finding pauses

Subtle cognitive changes in perimenopause are measurable, not only perceived. Word-finding pauses, reduced verbal fluency, and a sense of "slower processing" are the usual descriptions. These have been demonstrated objectively in perimenopausal women on neuropsychological testing, independent of mood (Weber et al., 2014). Suspect perimenopause when the pauses are new for you and cluster with sleep disruption or a change in your cycle.

No single sign is diagnostic. The pattern of two or more signs appearing together across several cycles is what warrants further evaluation.

Why a "normal FSH" doesn't rule out perimenopause

A single normal FSH result does not rule out perimenopause. FSH rises and falls within one cycle, and between consecutive cycles, during the early menopausal transition (Randolph et al., 2011). FSH is still frequently the first lab ordered when perimenopause is suspected, and a single "normal" result is one of the most common reasons you may be told you are too young to be perimenopausal.

The problem is biological, not technical. In the early transition, FSH varies dramatically within a single cycle and across consecutive cycles. The Endocrine Society and The Menopause Society both note that a single FSH measurement has limited diagnostic value in women who are still cycling. FSH can be elevated in one cycle and within range in the next (Endocrine Society guidelines; The Menopause Society). SWAN data show FSH does not rise in a straight line. It oscillates throughout the transition and only settles at elevated values in late transition and post-menopause (Randolph et al., 2011).

Guidelines have moved the same way. NICE guideline NG23 says to use FSH only to help confirm the diagnosis in women aged 40 to 45 with symptoms, or in women under 40. It also says not to use FSH while you are on combined hormonal contraception, because that suppresses the result. The European Society of Endocrinology guideline of October 2025 calls testing unnecessary over 45 and says it can be considered between 40 and 45. Where FSH is measured, that guideline says to draw it on day 2 to 5 of the cycle, or after more than 40 days without a period.

Two implications follow. First, a normal FSH on cycle day 3 in a 38-year-old does not rule perimenopause out. Second, while you are still cycling, the diagnosis is primarily clinical. It rests on cycle-pattern change and your symptoms, with labs as supporting context, not as a gate.

Better markers: what cycle-day matters, and what tests measure

If a single FSH is unreliable, what does give useful information? No test definitively diagnoses early perimenopause. Several tests, read in context, can support or weaken the clinical picture.

Estradiol-to-progesterone ratio across the cycle

Serum estradiol and progesterone vary by cycle phase. A common early-peri pattern is relatively preserved estradiol with falling luteal progesterone, sometimes described as relative estrogen dominance. Measuring estradiol around cycle day 3 and progesterone in the mid-luteal phase (~7 days after ovulation) gives values you can compare with expected ranges (Endocrine Society). Urinary metabolite testing such as the DUTCH test reports estrogen and progesterone metabolites across a collection period. It describes metabolite output; it is not a diagnostic for perimenopause.

Anti-Müllerian hormone (AMH)

AMH reflects your remaining ovarian follicle pool and can be drawn on any cycle day. Lower AMH is associated with a shorter time to menopause across populations, but it cannot date menopause for you as an individual. A January 2023 review in Human Reproduction Update, pooling 41 studies and 28,858 women, found individual prediction imprecise. Estimates and their confidence intervals spanned 2 to 12 years. The only AMH menopause test with FDA clearance, PicoAMH, is limited to ages 42 to 62 and must not be used to decide whether to stop contraception. No at-home perimenopause test currently holds FDA clearance for diagnosis. NICE guideline NG23 also advises against using AMH to identify perimenopause or menopause at 45 and over. AMH is one data point in context, not a perimenopause test.

Thyroid panel

Hypothyroidism mimics multiple perimenopause symptoms. So a panel including TSH, free T4, free T3, and thyroid antibodies is part of any responsible workup (Endocrine Society thyroid guidelines).

Cycle pattern itself

Variability of seven or more days between consecutive cycles, sustained over three months, is the STRAW+10 operational definition for entry into the early transition (Harlow et al., 2012). A documented cycle log is often more informative than any single lab. These descriptions are educational; your clinician interprets these tests in context.

What each early perimenopause test can and cannot tell you

What else could it be? Differential to consider before assuming peri

Several conditions overlap with early perimenopause. Anchoring on peri without considering them can delay correct diagnosis.

Thyroid dysfunction. Hypothyroidism and Hashimoto's thyroiditis can produce fatigue, sleep disruption, mood change, menstrual irregularity, and reduced exercise tolerance. Antibody-positive thyroid disease is common in women in their 30s and 40s, and it is frequently undiagnosed (Endocrine Society).

Polycystic ovary syndrome (PCOS). PCOS can present with cycle irregularity, mood symptoms, and metabolic features, sometimes worsening in your late 30s as insulin sensitivity declines. A history of irregular cycles since adolescence, androgen-related signs, or characteristic ovarian morphology distinguishes PCOS from new-onset peri (2023 international PCOS guideline).

HPA-axis dysregulation and chronic stress. Sustained stress alters cortisol rhythm and downstream sex-hormone signaling. Sleep disruption, anxiety, and luteal-phase changes can all arise from this pathway independent of perimenopause.

Postpartum recalibration. The year or two after pregnancy, especially after you stop breastfeeding, involves prolonged hormonal recalibration that can mimic early peri. Telling the two apart often means waiting one or two normal cycles after weaning before interpreting your symptoms.

Early signs vs other conditions that mimic them

Cycle-tracking: what to log before you book an appointment

Two to three months of structured tracking provides more diagnostic signal than most single-visit lab panels. The columns below capture the data points most useful at an evaluation.

A wearable can add to your log, within limits. A May 2026 update from the Apple Women's Health Study covered 338 participants and 94,118 nights. In the 18 months before the final period, 60% of participants spent more time awake after falling asleep, by an average of 7%. Time awake was 0.8% higher after menopause than before, against 0.2% from aging alone. Many participants showed no clear pattern, while 84% reported sleep changes they had noticed themselves.

Device makers report similar trends from their own data. Oura reported in October 2024 on more than 100,000 users. It said perimenopausal users lost up to 2 hours of sleep a week and showed heart rate variability 20 to 30% lower. That is a company report rather than peer-reviewed research, and Oura stated in August 2025 that its ring is not a medical device. No brand has published a perimenopause validation trial. Read the trend as a reason to look more closely with your clinician, not as a diagnosis.

Daily cycle log template

Three patterns matter most. (1) Cycle-length variability across consecutive cycles. (2) Clustering of sleep disruption, mood change, and hot flashes in the luteal phase or around ovulation. (3) Whether your symptoms are random or follow the cycle. A clinician evaluating an early peri picture looks first at the pattern, then at labs.

When the pattern points to a workup

Several situations warrant a structured clinical evaluation rather than continued self-monitoring. Consider booking a consult when any apply:

• Cycle-length variability of seven or more days between consecutive cycles, sustained for three months or longer.
• Sleep disruption that has persisted for three or more months and is not responding to sleep-hygiene measures.
• New-onset anxiety or mood change that is qualitatively different from prior baseline and is interfering with function.
• Hot flashes or night sweats, even infrequent, if you are in your 30s or early 40s.
• Heavy or prolonged bleeding, intermenstrual bleeding, or post-coital bleeding (these require evaluation regardless of perimenopause considerations).
• Family history of early menopause in a mother or sister.
• Symptom pattern not improving after evaluation and treatment for thyroid disease, anemia, or mental-health conditions.

A functional medicine workup for suspected early perimenopause typically includes your cycle history, a thyroid panel with antibodies, iron studies and ferritin, and fasting glucose and insulin. Timed sex-hormone testing is interpreted alongside your cycle log. The aim is to clarify the pattern and rule out mimics before any treatment conversation. For deeper context on the full transition, see the complete guide to perimenopause for women.

FAQ

Can perimenopause really start in your 30s?

Yes. The average age of menopause is approximately 51, and the transition typically begins four to eight years earlier. But cohort data including SWAN document a meaningful minority of women entering it in their late 30s. The STRAW+10 framework explicitly identifies a late reproductive stage in which subtle endocrine shifts begin while cycles still appear regular. Symptoms arriving in your 30s should not be dismissed on age alone. Pattern matters more than the calendar.

What is the most reliable test for early perimenopause?

There is no single reliable test. FSH varies substantially across cycles in the early transition, so a normal value does not rule peri out. AMH reflects ovarian reserve and trends downward with reproductive aging, but it predicts your timeline only modestly. The most useful diagnostic information is usually a documented cycle log over two to three months, combined with symptom tracking and a thyroid panel. It should be interpreted by a clinician familiar with the transition.

How is early perimenopause different from premature ovarian insufficiency?

Premature ovarian insufficiency (POI) is a distinct diagnosis, and its definition changed recently. A joint guideline from ESHRE, ASRM, CREWHIRL and the International Menopause Society was published in December 2024. It defines POI as disordered cycles, meaning absent or irregular periods, for at least four months, plus one FSH result above 25 IU/L. A repeat sample is needed only where the diagnosis is uncertain, and no particular cycle day is required. That guideline also puts prevalence at 3.5%, well above the figure of about 1% quoted for years. Guidance still differs by country: NICE asks for two raised FSH samples taken four to six weeks apart. Early perimenopause, by contrast, is the start of the natural transition before the typical age range, and your periods do not stop. POI requires specific evaluation, including karyotype, fragile X testing, and adrenal antibodies per Endocrine Society guidance, and it is managed differently.

Does perimenopause cause anxiety, or is the anxiety unrelated?

Both can be true. Population data including SWAN associate the menopausal transition with an increased incidence of new-onset and recurrent anxiety and depressive symptoms. Hormonal variability is one proposed mechanism. At the same time, anxiety in this age range can reflect life stressors, sleep deprivation, or thyroid disease. A clinician typically looks at your symptom timing relative to the cycle, your thyroid status, and your sleep before attributing anxiety to perimenopause alone.

Being treated for the wrong thing is a common experience. Biote, a hormone therapy company, commissioned a survey of more than 1,000 US women aged 30 to 60, released in November 2025. It found that 33% had been diagnosed with anxiety and that 39% felt they had been misdiagnosed. This is industry-commissioned market research rather than peer-reviewed evidence, so read it as a signal about how women experience care, not as a prevalence figure.

Should birth control be stopped before testing for perimenopause?

Combined hormonal contraception suppresses your own FSH, estradiol, and progesterone, so hormone testing while you are on it is uninformative for staging. Your cycle pattern is also obscured. Any decision to pause contraception for diagnostic clarity should be made with a prescribing clinician. Contraception remains necessary throughout the transition until menopause is confirmed. Some tests, such as thyroid panels and AMH, remain interpretable on contraception, and symptom tracking is useful regardless.

How long can early perimenopause last before periods stop?

The full menopausal transition averages four to eight years from the first detectable changes to the final menstrual period, with wide individual variation. If you notice the earliest signs in your mid-to-late 30s, you can be in some stage of the transition for a decade or more before menopause itself. That is why a multi-year framework, rather than a single "menopause moment," is more accurate to lived experience.

References

1. Harlow SD, et al. Journal of Clinical Endocrinology and Metabolism. 2012. https://pubmed.ncbi.nlm.nih.gov/22344196/
2. Cunningham AC, et al. npj Women's Health. 2025. https://www.nature.com/articles/s44294-025-00061-3
3. The Menopause Society. The Menopause Society. 2026. https://menopause.org/press-releases/international-differences-exist-in-knowledge-gaps-and-most-common-perimenopause-symptoms
4. Zeng W, et al. Frontiers in Neurology. 2025. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1460613/full
5. National Institute for Health and Care Excellence. NICE guideline NG23. 2026. https://www.nice.org.uk/guidance/ng23/chapter/recommendations
6. European Society of Endocrinology. European Journal of Endocrinology. 2025. https://academic.oup.com/ejendo/article/193/4/G49/8281862
7. Nelson SM, et al. Human Reproduction Update. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10152172/
8. US Food and Drug Administration. US Food and Drug Administration. 2018. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-diagnostic-test-aid-determination-menopausal-status
9. Apple Women's Health Study. Harvard T.H. Chan School of Public Health. 2026. https://hsph.harvard.edu/research/apple-womens-health-study/study-updates/sleep-patterns-and-changes-in-perimenopause/
10. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI. Human Reproduction Open. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11631070/
11. Biote. Business Wire. 2025. https://finance.yahoo.com/news/nearly-40-women-were-misdiagnosed-140300695.html

About the author

Medical disclaimer. The information on this page is provided for general education and is not individualized medical advice. At Interlinked Wellness, Anna Evans, MSN, APRN, FNP-C, provides personalized care based on your health history, symptoms, concerns, and goals. An individual consultation allows Anna to evaluate your specific situation and recommend an appropriate approach to care. Reading this page alone does not establish a patient-provider relationship. If you are experiencing a medical emergency, call 911 or your local emergency services.